If a diabetic patient being treated with an oral hypoglycemic agent develops dilutional hyponatremia, which one of the following could be responsible for this effect?
**Core Concept**
The question is testing the side effect profile of oral hypoglycemic agents, specifically those that can cause water retention and hyponatremia. Dilutional hyponatremia occurs when there is an excessive retention of water in the body, leading to a dilution of sodium levels.
**Why the Correct Answer is Right**
Some oral hypoglycemic agents, particularly the sulfonylureas and meglitinides, stimulate insulin release and can cause water retention by increasing renal sodium reabsorption. This effect is mediated by the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS), which leads to increased sodium and water reabsorption in the kidneys. The resulting hyponatremia is a well-documented side effect of these medications.
**Why Each Wrong Option is Incorrect**
**Option A:**
This option is incorrect because glitazones, such as pioglitazone and rosiglitazone, primarily work by increasing insulin sensitivity and do not have a significant effect on water retention or hyponatremia.
**Option B:**
This option is incorrect because alpha-glucosidase inhibitors, such as acarbose, work by delaying carbohydrate absorption and do not have a direct effect on water retention or hyponatremia.
**Option C:**
This option is incorrect because SGLT-2 inhibitors, such as empagliflozin and canagliflozin, work by increasing glucose excretion in the urine and do not have a significant effect on water retention or hyponatremia.
**Clinical Pearl / High-Yield Fact**
It's essential to monitor patients on oral hypoglycemic agents for signs of hyponatremia, particularly those with a history of heart failure or liver disease, as they may be more susceptible to this side effect.
**Correct Answer: A. Sulfonylureas and meglitinides.**